PD-L1 expression

1:44
The role of the pathologist in the field of lung cancer
Keith Kerr
3:37
Problems with PD-L1 expression testing in patients with NSCLC
Keith Kerr
2:10
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
Federico Cappuzzo
1:28
ATLANTIC: durvalumab in the fight against NSCLC
Marina Garassino
1:14
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
David Carbone
4:20
Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151
Toni Choueiri
1:13
Guiding NSCLC treatment with biomarkers
Alastair Greystoke
2:18
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
Thomas Powles
3:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Jacob Kettle
1:18
Checkpoint inhibitors in small cell lung cancer (SCLC)
David Spigel
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals